NASDAQ:ALPN - Nasdaq - US02083G1004 - Common Stock - Currency: USD
ALPN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. ALPN has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, ALPN is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -9.86% | ||
ROE | -11.07% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 64.87 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 9.56 | ||
Quick Ratio | 9.56 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
64.97
+0.01 (+0.02%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 78.86 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 13.4 | ||
P/tB | 13.4 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -9.86% | ||
ROE | -11.07% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 71.36% | ||
Cap/Sales | 0.74% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 9.56 | ||
Quick Ratio | 9.56 | ||
Altman-Z | 64.87 |